<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Anti-VEGF Therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/anti-vegf-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 27 Oct 2025 21:41:22 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Anti-VEGF Therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Nanoparticle Bevacizumab Improves Retinopathy in Mice</title>
		<link>https://bioengineer.org/nanoparticle-bevacizumab-improves-retinopathy-in-mice/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 21:40:53 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Anti-VEGF Therapy]]></category>
		<category><![CDATA[Intravitreal Drug Delivery]]></category>
		<category><![CDATA[Nanoparticle Bevacizumab]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[Ocular Nanomedicine]]></category>
		<category><![CDATA[pediatric ophthalmology advancements]]></category>
		<category><![CDATA[Retinopathy of Prematurity]]></category>
		<category><![CDATA[retinopathy of prematurity treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nanoparticle-bevacizumab-improves-retinopathy-in-mice/</guid>

					<description><![CDATA[In a groundbreaking advancement in pediatric ophthalmology, researchers have unveiled a novel therapeutic strategy that significantly mitigates retinal vasculopathy associated with retinopathy of prematurity (ROP) in an in vivo mouse model. This innovative approach leverages the efficacy of intravitreal bevacizumab nanoparticles, presenting a promising horizon for managing one of the leading causes of childhood blindness [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287408</post-id>	</item>
		<item>
		<title>Proteomic Changes Post Anti-VEGF in AMD Patients</title>
		<link>https://bioengineer.org/proteomic-changes-post-anti-vegf-in-amd-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 12 Oct 2025 18:01:01 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Anti-VEGF Therapy]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[Neovascular AMD]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[Proteomic Profiles]]></category>
		<guid isPermaLink="false">https://bioengineer.org/proteomic-changes-post-anti-vegf-in-amd-patients/</guid>

					<description><![CDATA[In the quest for understanding and treating neovascular age-related macular degeneration (nAMD), a significant breakthrough has been unveiled in the landscape of ophthalmic research. Recent findings from a study conducted by Lynch et al. dissects the intricate protein profiles present in the aqueous humor of patients undergoing anti-vascular endothelial growth factor (anti-VEGF) therapy. This work [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">279626</post-id>	</item>
	</channel>
</rss>
